UK: Funding For Second Kymriah Indication After Talks And Price Cut
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.